Luteoloside alleviates bleomycin-induced pulmonary fibrosis in mice via SIRT1-mediated protective effect against alveolar epithelial cell senescence
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-30 03:49
摘要：
Luteoloside, a flavonoid glycoside, has shown promise in alleviating bleomycin-induced pulmonary fibrosis in mice by targeting cellular senescence. The study reveals that luteoloside exerts its protective effects through the SIRT1 pathway, enhancing mitochondrial function and reducing oxidative stress. This research highlights the potential of luteoloside as a therapeutic agent for idiopathic pulmonary fibrosis, addressing a significant unmet medical need.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Luteoloside alleviates bleomycin-induced pulmonary fibrosis in a dose-dependent manner.
Mechanistically, luteoloside's protective effects were mediated through SIRT1.
The study provides new insights into the mechanisms of luteoloside in pulmonary fibrosis.
真实性检查
否
AI评分总结
Luteoloside, a flavonoid glycoside, has shown promise in alleviating bleomycin-induced pulmonary fibrosis in mice by targeting cellular senescence. The study reveals that luteoloside exerts its protective effects through the SIRT1 pathway, enhancing mitochondrial function and reducing oxidative stress. This research highlights the potential of luteoloside as a therapeutic agent for idiopathic pulmonary fibrosis, addressing a significant unmet medical need.